Hey Oncodoc, what are your thoughts on the ligand-conjugate approach that Endocyte is using? Are you aware of any drugs that have used a ligand approach? I am wondering it this would be an entirely new entity that the FDA has not seen before. Like a first in class type of drug.
Looks interesting! Market cap still cheap based on cash and phase 3 product. Questions is, should one invest in 2013 or early 2014 before DSMB review? Are there any real catalysts for the stock in 2013? Thanks for bringing to our attention!
There is 2 new drug application in 2013. I would invest invest ant time the stock dips below 10.00 and definetley before Europe decision in 4Q 2013. If approved in Europe ECYT will trade above $20.00. I recommend that you read conference notes posted and presentation in the website. Good luck.
I need one of our resident scientists to opine on the attachment of the c's to a small molecule and the quality of their linker technology and the strength of ECYT's. Or, I guess I could invest some time and listed to their cc. Any scientific experts here following them?
So their approach is to use a ligand to target the cancer cell, and attached to the ligand is their linker and then a small cell killing molecule. Their small molecule works by inhibiting or breaking up a protein called tubulin. Tubulin is critical to a cell to divide, it makes up what is called the spindle fibers that pull the chromosomes apart when a cell divides. So mechanistically, very much the same way that Immunogen's DM1 works. The big difference here is the ligand vs antibody. I think the antibody approach is extremely well proven as we have a number of approved drugs and history of their use for well over 10 years now. The ligand approach is still pretty new, and I am not aware of any approved drugs using a ligand approach. To me, these guys are quite a ways behind SGEN and IMGN, and even if the ligand approach works better than antibodies, they are going to be late to the party. That does not mean you cannot make money on the optimism of their success. They might have a few years of really good compelling clinical data that could drive the stock price up. My two cents.l